Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Nkarta, Inc. (“Nkarta” or the “Company”) (NASDAQ: NKTX) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Nkarta investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you.
- 04/08/2024
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
- BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Nkarta, Inc. (“Nkarta” or the “Company”) (NASDAQ: NKTX) investors concerning the Company's possible violations of federal securities laws. On March 21, 2024, Nkarta announced that it had “deprioritized” its acute myeloid leukemia program, NKX101, stating that the “response rate was meaningfully lower than that from the first 5 previously reported patients.” On this news, Nkarta's stock price f.
- 04/05/2024
|
The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Nkarta, Inc. (“Nkarta” or the “Company”) (NASDAQ: NKTX) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On March 21, 2024, Nkarta announced that it had “deprioritized” its acute myeloid leukemia program, NKX101, stating that the “response rate was meaningfully lower than that from the.
- 04/05/2024
|
Nkarta to Participate in Upcoming Investor Conferences
- SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in two upcoming investor conferences:
- 04/03/2024
|
Huge Insider Buying From Buffett, an NFL Team Owner, a New CEO
- Yet again, the Oracle of Omaha has bolstered his stake in a media giant's tracking stocks.
- 03/31/2024
|
Nkarta: NK Cell Therapy Advancement On Two Fronts
- Release of results from the phase 1 study, using NKX019 for the treatment of patients with relapsed/refractory NHL, expected mid-2024; this is using a compressed dosing schedule. The global non-Hodgkin's Lymphoma market is expected to reach $20 billion by the end of 2036. NKX019 is also being used to target patients with autoimmune disorders like Lupus Nephritis; the first patient in the phase 1 study is to be dosed in 1st half of 2024.
- 03/25/2024
|
Nkarta Announces Pricing of $240 Million Underwritten Offering
- SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the pricing of an underwritten offering of 21,010,000 shares of its common stock at a price of $10.00 per share and pre-funded warrants to purchase 3,000,031 shares of common stock. The pre-funded warrants are being sold at a price of $9.9999 per warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price.
- 03/25/2024
|
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
- SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the fourth quarter and year ended December 31, 2023.
- 03/21/2024
|
3 Overlooked Stocks Ready to Capture the Market by Storm
- Some overlooked stocks remain obscure and wait for astute investors to spot them. This happens even in the middle of Wall Street's busy trading floors and the digital chaos of online investing platforms.
- 03/19/2024
|
Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders
- Nkarta's stock soared 690% in six months, buoyed by promising cell therapy technology for cancer and autoimmune diseases. Financially healthy, with a high current ratio and a cash runway extending into 2026, indicating low near-term dilution risk. Despite high short interest, market sentiment is robust, driven by insider buying and significant institutional investment.
- 03/13/2024
|
3 Silent Tech Titans-in-the-Making: Invest Before They Skyrocket
- Among tech investments, the search for the next titan resembles a deep dive into the ocean for pearls. The periodic portfolio shifts toward solid tech contenders with high-yield potential as the digital space evolves.
- 02/29/2024
|
Nkarta to Participate in Upcoming Investor Conferences
- SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in three upcoming investor conferences:
- 02/28/2024
|
Last Call! 7 Small-Cap Stocks Ready to Explode in Value
- The article lists seven small-cap stocks for those looking for opportunities that promise exponential return potential. From innovative biotech firms to edgy technology providers, small-cap stocks are making waves in various industries, offering the chance to capitalize on their leads.
- 02/20/2024
|
3 Under-the-Radar Stocks Set to Soar 300% by 2026
- In the stock markets, where giants often steal the investment spotlight, hidden gems await discovery. Beyond the limelight lay under-the-radar stocks for 300% growth, teeming with potential and ready to soar to heights unimaginable to many investors.
- 02/08/2024
|
3 Sleeper Stocks With Serious Potential to Make You a Millionaire
- Amidst the bustle of large tech giants taking up the artificial intelligence ( AI ) space and news headlines of leading pharmaceutical juggernauts marking key development milestones, many quality stocks can easily fly under an investor's radar. Whether those are smaller companies producing innovative solutions or undervalued companies slowly working toward profitability, there lay hundreds of opportunities for investors that many investors have glazed over.
- 02/06/2024
|
3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential
- The biotech sector is one of my favorite sectors since it is not only constantly growing and with companies that are always doing wonderful research, products, and solutions, but it is also a sector that is constantly innovating and contributing to the health of the human being. If you want to participate as an investor in this sector and take advantage of companies that have great growth opportunities, here are three biotech stocks with potential that you can consider adding to your portfolio.
- 02/05/2024
|
Unseen Giants: 3 Stocks Quietly Preparing for a 10X Surge
- Some stocks silently position themselves for monumental bursts. These companies, spanning the semiconductor, healthcare and biotechnology sectors, are emerging as unseen giants with the potential for a 10X surge.
- 02/04/2024
|
Penny Stocks To Buy Now? 4 To Watch Before 2024
- As we enter 2024, investors wonder if it will be another volatile year for stocks. Maybe we see some stabilization after 2023's ups and downs; maybe not.
- 12/19/2023
|
All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to Buy
- Nkarta, Inc. (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 12/08/2023
|
Nkarta to Participate at Upcoming Investor Conferences
- SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation at two upcoming investor conferences:
- 11/07/2023
|
Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug
- Nkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidate, NKX019, for the treatment of lupus nephritis.
- 10/18/2023
|
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
- SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, October 17, 2023 at 8:00 a.m.
- 10/16/2023
|
3 Promising Biotech Stocks That Will Make Early Investors Rich
- For investment ideas that can potentially lead to life-changing gains, few sectors are as viable as biotech stocks to make you rich. Fundamentally, the biotechnology sector offers potential therapeutic innovations that could change paradigms for patient care.
- 10/02/2023
|
Nkarta to Participate at Upcoming Investor Conference
- SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation at an upcoming investor conference:
- 08/03/2023
|
3 Hidden Penny Stocks That Could Turn $100 into $10,000
- Investing in penny stocks can feel like finding needles in a haystack, and can certainly be an uphill battle for most investors. Different from investing in well-established businesses, you can't hold your way to profit with most small businesses.
- 07/31/2023
|
Here's Why Nkarta, Inc. (NKTX) is Poised for a Turnaround After Losing -39.31% in 4 Weeks
- Nkarta, Inc. (NKTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 06/28/2023
|
Why Shares of Nkarta Are Slumping Tuesday
- Nkarta's lead therapy showed limited effectiveness in treating acute myeloid leukemia. Last week, there was a rash of insider selling by company executives.
- 06/27/2023
|
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
- SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, June 27, 2023 at 8:00 a.m.
- 06/26/2023
|
Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
- SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will present preliminary data from its Phase 1 dose escalation clinical trial of NKX019 at two upcoming scientific conferences in June 2023: the European Hematology Association (EHA) 2023 Hybrid Congress and the 17th International Conference on Malignant Lymphoma (17-ICML). NKX019 is an allogeneic, off-the-shelf cell therapy candidate comprising NK cells derived from healthy donors and engineered to target the B-cell antigen CD19.
- 05/11/2023
|
7 Stocks With Promising Upside Potential for 100% Returns
- While your friendly financial advisor will probably never recommend these terribly risky enterprises, sometimes, you're just in the mood for stocks with 100% upside potential. And with these ideas, you're going to get that and more, assuming the stars align correctly.
- 05/07/2023
|
Nkarta to Participate at Upcoming Investor Conferences
- SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at two upcoming investor conferences:
- 04/12/2023
|
3 Biotech Stocks to Watch for Potential Breakthroughs
- Biotech stock fortunes hinge upon potential, progress, and the ultimate realization of drugs and devices that treat diseases. Stringent regulatory processes and long development times result in substantial costs.
- 04/11/2023
|
Nkarta: Going Down Despite Solid Data Due To Fate's Debacle
- NKTX has consistently produced solid data from its NK cell programs. Despite that, the stock is going down.
- 03/26/2023
|
Nkarta to Participate at Upcoming Investor Conferences
- SOUTH SAN FRANCISCO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at three upcoming investor conferences:
- 02/09/2023
|
7 Cheap But Risky Biotech Stocks
- Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.
- 01/18/2023
|
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program
- Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ET Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ET
- 12/02/2022
|
Nkarta: Under The Radar Company With Brilliant Results
- NKTX came out with strong data in heavily pretreated AML patients in April. Data was at least as good as Fate's data, which is valued nearly 4x higher.
- 11/10/2022
|
Nkarta to Participate at Upcoming Investor Conferences
- SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at three upcoming investor conferences:
- 11/02/2022
|
7 Unknown Biotech Stocks That Could Rocket in 2023
- Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.
- 09/23/2022
|
Should You Buy Nkarta (NKTX) Ahead of Earnings?
- Nkarta (NKTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 08/10/2022
|
Trial Results Set to Make or Break Small-Cap Pharma Stocks
- One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administration approval. If that happens, Jefferies analyst Chris Howerton believes the treatment should have “no issue” topping annual sales of $1 billion, reported BioPharma Dive.
- 07/06/2022
|
Nkarta Stock a Bargain Compared to Fate Therapeutics
- Investors who like Fate Therapeutics Inc. ( FATE , Financial) should love Nkarta Inc. ( NKTX , Financial).
- 06/08/2022
|
Nkarta to Participate at Upcoming Investor Conference
- SOUTH SAN FRANCISCO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at an upcoming investor conference:
- 05/31/2022
|
Nkarta: A Promising Natural Killer Cell Play
- The market has favorably appreciated Nkarta's recent readout of its NKX101 and NKX019 drug candidates, with the share price more than doubling. I see a huge disconnect between analyst targets and the actual share price, possibly due to the market's lack of insight in the highly innovative nature of the science.
- 05/20/2022
|
What Makes Nkarta, Inc. (NKTX) a New Buy Stock
- Nkarta, Inc. (NKTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 05/18/2022
|
Up 131% in a Day, Is This Hot Stock a Buy?
- Some of its early clinical data look much better than expected.
- 04/28/2022
|
Nkarta Scores Huge Gain on Cancer Treatment Results
- Bargain hunters may want to feast their eyes on a South San Francisco-based biotech focusing on cancer treatments.
- 04/25/2022
|
Here is why Nkarta is 40% up
- Nkarta Inc. (NASDAQ: NKTX) is up 40% after announcing positive preliminary Phase 1 findings from its dose-finding trials of NKX101 and NKX019 in hematological malignancies. NKX101 and NKX019 are two leading chimeric antigen receptor natural killer cell therapies the company is developing for two different sets of hematologic malignancies.
- 04/25/2022
|
Why Is Nkarta (NKTX) Stock Soaring 90% Today?
- Nkarta (NKTX) stock is rocketing higher on Monday after the company released preliminary data from a Phase 1 clinical trial. The post Why Is Nkarta (NKTX) Stock Soaring 90% Today?
- 04/25/2022
|
Investors Cheer Nkarta's First NK Cell Data With Multiple Complete Responses
- Nkarta Inc (NASDAQ: NKTX) has revealed the first human results from its two lead off-the-shelf NK cell therapies, with the high-dose regimens exhibiting multiple complete responses in blood cancer patients. For NKX101, three patients achieved a complete response (CR) among.
- 04/25/2022
|
Nkarta stock skyrockets on heavy volume after upbeat results from cancer-treatment trial
- Shares of Nkarta Inc. NKTX, +95.82% skyrocketed 92.8% in very active morning trading, enough to make the stock the biggest gainer and most active listed on major U.S. exchanges, after the biopharmaceutical company announced positive results from a Phase 1 trial of its cancer treatments. The rally comes after the stock closed at a record low of $7.77 on Friday.
- 04/25/2022
|
Struggling Biopharma Stock Blasts Higher After Upbeat Data
- Biopharmaceutical stock Nkarta Inc (NASDAQ:NKTX) is skyrocketing today, up 91.4% at $14.87 at last check, after the company announced positive preliminary data for two of its experimental cell therapy treatments.
- 04/25/2022
|
Why Nkarta Stock Is Soaring Today
- Nkarta Inc (NASDAQ: NKTX) shares are trading higher Monday morning after the company announced positive preliminary Phase 1 data from independent dose finding studies. The positive data was for the company's two lead chimeric antigen receptor natural killer cell therapy.
- 04/25/2022
|
Nkarta's stock jumps 42% after announcing positive Phase 1 data for experimental CAR-T therapies
- Shares of Nkarta Inc. NKTX, -2.51% soared 42.7% in premarket trading on Monday after the company reported positive Phase 1 clinical data for two experimental CAR-T therapies. Three of five patients with pre-treated acute myeloid leukemia reported a complete response after undergoing treatment with one of the investigational therapies.
- 04/25/2022
|
Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates
- Call scheduled for Monday, April 25, 2022 8:00 a.m. ET
- 04/22/2022
|
Nkarta to Participate at Upcoming Investor Conference
- SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at an upcoming investor conference:
- 04/08/2022
|
All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to Buy
- Nkarta, Inc. (NKTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 04/04/2022
|
Nkarta to Present Preclinical Data from Engineered NK Cell Platform at the American Association for Cancer Research 2022 Annual Meeting
- SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will present four posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting to be held April 8 to 13, 2022.
- 03/08/2022
|
Nkarta to Participate at Upcoming Investor Conferences
- SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:
- 02/10/2022
|
Can Nkarta (NKTX) Climb 270% to Reach the Level Wall Street Analysts Expect?
- The mean of analysts' price targets for Nkarta (NKTX) points to a 270.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 11/15/2021
|
Nkarta to Participate at Upcoming Investor Conferences
- SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:
- 11/04/2021
|
Nkarta Expects Initial Data From CAR NK Cell Therapy In Blood Cancer In 2022
- Nkarta Inc (NASDAQ: NKTX) has updated guidance on initial data readout of Phase 1 trial of NKX101 in relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes. Data from the engineered CAR NK cell therapy candidate targeting the NKG2D ligand is expected in 1H of 2022, against the end of 2021 expected earlier.
- 10/08/2021
|
Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs
- SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced NKX019 and NKX101 clinical development program updates.
- 10/07/2021
|
Nkarta to Present Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting
- SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced four presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and Pre-Conference Programs to be held November 10-14, 2021.
- 10/01/2021
|
Nkarta to Participate at Upcoming Investor Conference
- SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at this upcoming investor conference:
- 09/14/2021
|
Nkarta Unveils Plans For New San Francisco HQ, Manufacturing Site
- Nkarta Therapeutics Inc (NASDAQ: NKTX) will be moving into an 88,000-square-foot facility that will not only serve as its newest headquarters but will support the research, development, and future commercial manufacturing of its cell therapy pipeline. The Company did not disclose the cost of the project.
- 07/14/2021
|
Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters
- SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it has signed a lease agreement for a facility to support research and development and future commercial manufacturing of Nkarta's cell therapy pipeline. The new facility will also serve as the company's headquarters with office space and research facilities. The manufacturing center will be custom designed to complement Nkarta's state-of-the-art technology platform and optimize the production of its multiple off-the-shelf NK cell therapy investigational products. Nkarta plans to produce materials for potential pivotal clinical trials and commercial launch at the new center.
- 07/14/2021
|
Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term
- SOUTH SAN FRANCISCO, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that Chief Executive Officer Paul Hastings has been elected as the Chair of the Biotechnology Innovation Organization (BIO) Board of Directors for the 2021-2022 term.
- 06/14/2021
|
How Much Will the Nkarta Deal Help CRISPR Therapeutics?
- Unfortunately, this isn't an endorsement by a big drug developer.
- 06/06/2021
|
Nkarta Reports First Quarter 2021 Financial Results and Business Progress
- SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the first quarter ended March 31, 2021.
- 05/13/2021
|
Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer
- Nkarta Inc (NASDAQ: NKTX) has collaborated with CRISPR Therapeutics AG(NASDAQ: CRSP) to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program. The companies will split all the R&D costs and any worldwide profits, 50/50.
- 05/07/2021
|
NKTX Stock: Over 10% Increase Pre-Market Explanation
- The stock price of Nkarta Inc (NASDAQ: NKTX) increased by over 10% pre-market. This is why it happened.
- 05/07/2021
|
Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies
- SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to study NKX019 in patients with relapsed or refractory B cell malignancies.
- 04/28/2021
|
Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress
- SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2020.
- 03/25/2021
|
Biotech Shares Have Soared Since 2020's Wave of IPOs
- Indicative of investors' enthusiasm for new biotechs, the average gain in share price for the top 10 companies of the sector that went public in 2020 now tops 100%.
- 02/17/2021
|
Nkarta Reports Third Quarter 2020 Financial Results
- SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the third quarter ended September 30, 2020, and highlighted recent corporate accomplishments.
- 11/12/2020
|
Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101
- First Multi-Center Clinical Trial to Investigate an Engineered NK Cell Targeting NKG2D First Multi-Center Clinical Trial to Investigate an Engineered NK Cell Targeting NKG2D
- 11/12/2020
|
Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer
- SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced a preclinical update on NKX019, its investigational allogeneic cancer immunotherapy that uses donor-derived natural killer (NK) cells engineered with a membrane-bound form of IL15 and a chimeric antigen receptor (CAR) targeting the CD19 antigen.
- 11/09/2020
|
Nkarta Announces November & December 2020 Investor Conference Schedule
- SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:
- 11/05/2020
|
The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 6)
ADiTx Therapeutics Inc (NASDAQ: ADTX) (announced introduction of AditxtScore for COVID-19 to be used in detecting...
- 08/07/2020
|
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
ABIOMED, Inc. (NASDAQ: ABMD)
Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) (announced a U.S. government grant for a...
- 08/06/2020
|
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
- Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
- 08/02/2020
|
Virtusa, Nkarta See Activist ActionsÁ
- New Mountain Vantage Advisers disclosed an interest of 2,979,665 shares of enterprise IT-services firm Virtusa. New Enterprise Associates revealed an initial position in Nkarta, an oncology biotech firm, of 2,902,115 shares.
- 07/31/2020
|
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 29)
Abbott Laboratories (NYSE: ABT)
ABIOMED, Inc. (NASDAQ: ABMD)
Adamis Pharmaceuticals Corp (NASDAQ: ADMP)
Annexon...
- 07/30/2020
|
The Daily Biotech Pulse: Merck's Breakthrough Therapy Designation, Sonoma Surges On Sanitizer News, Sanofi-Glaxo And More
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 28)
Axonics Modulation Technologies Inc (NASDAQ: AXNX)
Capricor Therapeutics Inc (NASDAQ: CAPR)
Fulgent Genetics Inc...
- 07/29/2020
|
The Daily Biotech Pulse: Spectrum's Positive Dementia Readout, Pfizer, BioNTech Start Late-Stage Coronavirus Trial, resTORbio Receives COVID-19 Funding
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 27)
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT)
Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO)...
- 07/28/2020
|
Nkarta raises nearly $290 million in IPO
- Nkarta Inc. said late Tuesday it raised $289.8 million in its recent public offering after underwriters exercised all their options for shares to cover overallotments. On Friday, the biotech company priced 16.1 million shares at $18 and offered underwriters options for an additional 2.1 million, but on the first day of trading, shares rocketed to a high of $58.69. In the meantime, shares have settled a bit, shedding 20% on Monday, and closing down 6.4% at $36.05 on Tuesday, for market cap of $1.1 billion.
- 07/14/2020
|
Nkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares
- SOUTH SAN FRANCISCO, Calif., July 14, 2020 -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies.
- 07/14/2020
|
U.S. IPO Weekly Recap: Preclinical Biotech Nkarta Pops 166% In A 5 IPO Week
- Three biotechs, two Chinese issuers, and one SPAC went public this past week. Preclinical oncology biotech Nkarta popped 166% in the best first-day return for a $10+ million IPO since 2015.
- 07/12/2020
|
Nkarta's stock triples out of the gate, then pulls back
- Shares of Nkarta Inc. tripled out of the gate Friday, after the biotechnology company's initial public offering priced above its expected range. The first trade of the stock was at $54.75, or 204.2% above the IPO price of $18, at 11:17 a.m. Eastern for about 159,000 shares. The company raised about $252 million in the IPO, which priced above the expected range of $16 to $17. The stock has pulled back since the open, and was last up 168% at $48.25. The company went public on a day that the Renaissance IPO ETF fell 1.0%, while the S&P; 500 edged up 0.3%.
- 07/10/2020
|
Biotech Nkarta prices IPO at $18 a share, above its price range
- Nkarta Inc. priced its initial public offering Friday at $18 a share, above its price range of $16 to $17, selling 14 million shares to raise about $252 million. The company upsized the deal on Thursday and raised the price range from a prior plan to offer 10 million shares priced at $14 to $16 a share. Cowen, Evercore ISI, Stifel and Mizuho Securities are the joint bookrunning managers of the IPO. The stock is expected to start trading on Nasdaq later Friday under the ticker symbol "NKTX." Nkarta is looking to go public at a time that the Renaissance IPO ETF has soared 61.7% over the past three months, while the iShares Nasdaq Biotechnology ETF has climbed 23.6% and the S&P; 500 has advanced 13.6%.
- 07/10/2020
|
Nkarta Announces Pricing of Initial Public Offering
- SOUTH SAN FRANCISCO, July 10, 2020 -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat.
- 07/10/2020
|
U.S. IPO Week Ahead: Third Quarter Kicks Off With China's Largest Gay Dating App
- BlueCity Holdings plans to raise $85 million at a $614 million market cap. Quhuo plans to raise $27 million at a $450 million market cap. Nkarta plans to raise
- 07/03/2020
|
Nkarta Begins U.S. IPO Rollout
- Nkarta has filed to raise $100 million in a U.S. IPO, although the final figure may differ. The firm is developing cell therapies for blood and other cancers. N
- 06/22/2020
|
U.S. IPO Weekly Recap: Royalty Pharma Takes The Crown In 5 IPO Week
- Five IPOs and one SPAC went public this past week led by Royalty Pharma. Healthcare continued to dominate, with all five IPOs coming from the sector. Seven IPOs
- 06/20/2020
|
